Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy
- 31 August 2008
- journal article
- review article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 35, S9-S20
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- A kit method for the high level synthesis of [211At]MABGBioorganic & Medicinal Chemistry, 2007
- Ifosfamide/carboplatin/etoposide (ICE) as front‐line, topotecan/ cyclophosphamide as second‐line and oral temozolomide as third‐line treatment for advanced neuroblastoma over one year of ageActa Paediatrica, 2004
- Radiation-induced bystander effects — implications for cancerNature Reviews Cancer, 2004
- Radiation-induced genomic instability and bystander effects: related inflammatory-type responses to radiation-induced stress and injury? A reviewInternational Journal of Radiation Biology, 2003
- Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft modelNuclear Medicine and Biology, 1996
- No-carrier-added meta-[123I]iodobenzylguanidine: Synthesis and preliminary evaluationNuclear Medicine and Biology, 1995
- Meta-[131I]iodobenzylguanidine uptake andmeta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell linesJournal of Neuro-Oncology, 1995
- Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastomaEuropean Journal of Cancer, 1995
- N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatmentEuropean Journal of Cancer, 1994